Skip to main
TXG

10X Genomics (TXG) Stock Forecast & Price Target

10X Genomics (TXG) Analyst Ratings

Based on 13 analyst ratings
Hold
Strong Buy 15%
Buy 15%
Hold 69%
Sell 0%
Strong Sell 0%

Bulls say

10x Genomics is a leading life science technology company with a diverse product portfolio, including its Chromium platform for studying biological components. The company has a strong financial position, with expected after-tax NPV5% of US$1,491M and IRR of 37.3%, and plans for sustainable growth through internally funded development projects. Its solid track record of shareholder returns, including repurchasing 3.2% of shares in 2025 and a planned US$350M return in 2026, demonstrates the company's commitment to driving value for investors.

Bears say

10x Genomics is facing challenges as their Q2 production and sales figures fell below expectations due to lower-grade and lower-gold-recovery areas in the Media Luna project. This resulted in YTD output falling within the lower half of the company's guidance and highlights the need for improved grades in the second half of the year. While the company's plans for the Media Luna North project may help in grade improvement, it may not be enough to significantly improve the company's financial performance.

10X Genomics (TXG) has been analyzed by 13 analysts, with a consensus rating of Hold. 15% of analysts recommend a Strong Buy, 15% recommend Buy, 69% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 10X Genomics (TXG) Forecast

Analysts have given 10X Genomics (TXG) a Hold based on their latest research and market trends.

According to 13 analysts, 10X Genomics (TXG) has a Hold consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44.15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44.15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

10X Genomics (TXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.